Group 1 - The core viewpoint of the news is that Shengbang Co., Ltd. has shown a positive stock performance with a 2.01% increase in price on January 6, reaching 71.68 yuan per share, and a total market capitalization of 443.02 billion yuan [1] - As of January 6, 2023, the stock has increased by 4.43% year-to-date, with a 3.46% rise over the last five trading days and an 8.44% increase over the last 20 days, although it has decreased by 11.31% over the last 60 days [1] - The company specializes in high-performance and high-quality analog integrated circuits, with its main business revenue composition being 61.75% from power management products and 38.04% from signal chain products [1] Group 2 - As of September 30, 2025, Shengbang Co., Ltd. reported a total revenue of 2.801 billion yuan, reflecting a year-on-year growth of 14.55%, and a net profit attributable to shareholders of 343 million yuan, which is a 20.47% increase compared to the previous year [2] - The company has distributed a total of 557 million yuan in dividends since its A-share listing, with 250 million yuan distributed over the last three years [3] - The number of shareholders increased by 128.90% to 110,800 as of September 30, 2025, while the average number of circulating shares per person decreased by 56.30% to 5,351 shares [2]

Core Viewpoint - Hongta Securities has shown a mixed performance in its stock price, with a year-to-date increase of 3.79% but a decline of 8.01% over the past 60 days, indicating potential volatility in its market position [2]. Group 1: Stock Performance - On January 6, Hongta Securities' stock rose by 2.04%, reaching a price of 8.50 CNY per share, with a total market capitalization of 40.093 billion CNY [1]. - The stock has experienced a net inflow of 6.3591 million CNY from major funds, with significant buying activity from large orders [1]. - Over the past five trading days, the stock has increased by 1.55%, while it has seen a slight decline of 0.23% over the last 20 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Hongta Securities reported a revenue of 1.762 billion CNY, reflecting a year-on-year growth of 8.46%, and a net profit attributable to shareholders of 864 million CNY, which is a 32.59% increase [2]. - The company has distributed a total of 2.862 billion CNY in dividends since its A-share listing, with 1.462 billion CNY distributed over the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Hongta Securities was 79,700, a decrease of 6.44% from the previous period, while the average number of circulating shares per person increased by 6.88% to 59,175 shares [2]. - The top ten circulating shareholders include new entrants such as the Guotai CSI All-Index Securities Company ETF, holding 36.5765 million shares, while Hong Kong Central Clearing Limited has exited the top ten list [3].

Core Viewpoint - Pacific Securities has shown a positive stock performance with a 3.65% increase year-to-date and a 2.16% rise in the last five trading days, despite a 7.19% decline over the past 60 days [2]. Group 1: Stock Performance - As of January 6, Pacific's stock price increased by 2.16% to 4.26 CNY per share, with a trading volume of 2.59 billion CNY and a turnover rate of 0.90%, resulting in a total market capitalization of 29.038 billion CNY [1]. - The stock has experienced a 3.65% increase since the beginning of the year, with a 2.16% rise over the last five and twenty trading days, but a decline of 7.19% over the last sixty days [2]. Group 2: Financial Performance - For the period from January to September 2025, Pacific achieved a revenue of 1.037 billion CNY, representing a year-on-year growth of 19.88%, and a net profit attributable to shareholders of 246 million CNY, marking an 80.26% increase [2]. - The company has distributed a total of 956 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased by 2.59% to 365,200, with an average of 18,666 shares held per shareholder, a decrease of 2.52% [2]. - The top ten circulating shareholders include notable entities such as Guotai Junan CSI All-Share Securities Company ETF, which holds 176 million shares, and Hong Kong Central Clearing Limited, holding 141 million shares, both showing significant increases in holdings [3].

近期北交所融资融券交易概况 | 日期 | 融资融券余额 | 较上一交易日增减 | 融资余额 | 融资余额较上一交易日 | 融券余额 | | --- | --- | --- | --- | --- | --- | | | （万元） | （万元） | （万元） | 增减（万元） | （万元） | | 2026.01.05 | 813847.14 | 17051.44 | 813815.86 | 17050.31 | 31.28 | | 2025.12.31 | 796795.70 | -2304.39 | 796765.55 | -2310.11 | 30.15 | | 2025.12.30 | 799100.09 | -2169.14 | 799075.66 | -2169.19 | 24.43 | | 2025.12.29 | 801269.23 | 3378.55 | 801244.85 | 3379.19 | 24.38 | | 2025.12.26 | 797890.68 | 2788.90 | 797865.66 | 2791.38 | 25.02 | | 2025.12.25 | 795101.77 ...

Core Viewpoint - MediXis has shown a positive stock performance with a year-to-date increase of 10.87% and significant gains in recent trading periods, indicating strong market interest and potential growth in the biopharmaceutical sector [2]. Group 1: Stock Performance - As of January 6, MediXis's stock price increased by 2.01%, reaching 62.53 CNY per share, with a trading volume of 30.23 million CNY and a turnover rate of 0.36%, resulting in a total market capitalization of 8.40 billion CNY [1]. - The stock has risen by 8.58% over the last five trading days and 17.45% over the last twenty days, while experiencing a slight decline of 1.23% over the past sixty days [2]. Group 2: Company Overview - MediXis, established on February 2, 2004, and listed on November 5, 2019, is located in the Pudong New Area of Shanghai and specializes in providing comprehensive new drug research and development services to pharmaceutical companies and other drug research institutions [2]. - The company's revenue composition includes 50.34% from preclinical research and 49.64% from drug discovery and pharmaceutical research, with a minor contribution of 0.01% from other services [2]. - MediXis is categorized under the pharmaceutical and biological industry, specifically in medical services and medical research outsourcing, and is associated with concepts such as CRO, specialized and innovative enterprises, margin financing, MSCI China, and small-cap stocks [2]. Group 3: Financial Performance - For the period from January to September 2025, MediXis reported a revenue of 843 million CNY, reflecting a year-on-year growth of 5.14%, while the net profit attributable to shareholders was -29.68 million CNY, showing a significant increase of 76.93% compared to the previous year [2]. - Since its A-share listing, MediXis has distributed a total of 158 million CNY in dividends, with cumulative payouts of 33.94 million CNY over the past three years [3]. Group 4: Shareholder Information - As of September 30, the number of shareholders for MediXis reached 16,500, an increase of 27.83% from the previous period, with an average of 8,149 circulating shares per person, which decreased by 21.96% [2].

Core Viewpoint - Jinlong Automobile has shown a positive stock performance recently, with a notable increase in revenue and net profit year-on-year, indicating strong operational growth and investor interest [1][2]. Group 1: Stock Performance - On January 6, Jinlong Automobile's stock rose by 2.15%, reaching 17.58 CNY per share, with a trading volume of 36.95 million CNY and a turnover rate of 0.30%, resulting in a total market capitalization of 12.606 billion CNY [1]. - Year-to-date, the stock price has decreased by 0.90%, but it has increased by 3.17% over the last five trading days, 7.20% over the last twenty days, and 36.81% over the last sixty days [1]. Group 2: Financial Performance - For the period from January to September 2025, Jinlong Automobile achieved an operating revenue of 16.329 billion CNY, representing a year-on-year growth of 13.40% [2]. - The net profit attributable to shareholders for the same period was 247 million CNY, showing a significant year-on-year increase of 223.71% [2]. Group 3: Shareholder and Market Information - As of September 30, 2025, the number of shareholders for Jinlong Automobile was 61,200, a decrease of 5.02% from the previous period, while the average number of circulating shares per person increased by 5.28% to 11,706 shares [2]. - The company has distributed a total of 862 million CNY in dividends since its A-share listing, with 104 million CNY distributed over the last three years [2].

Core Viewpoint - On January 5, Nanbaichuan's stock fell by 8.31%, with a trading volume of 750 million yuan, indicating market volatility and investor sentiment concerns [1]. Group 1: Stock Performance - On January 5, Nanbaichuan experienced a financing buy-in amount of 65.71 million yuan and a financing repayment of 58.54 million yuan, resulting in a net financing buy of 7.17 million yuan [1]. - As of January 5, the total balance of margin trading for Nanbaichuan was 117 million yuan, which represents 7.07% of its circulating market value [1]. Group 2: Company Overview - Nanbaichuan New Energy Co., Ltd. is located in Yuehu Industrial Zone, Taishun County, Zhejiang Province, and was established on October 29, 2007, with its listing date set for December 23, 2025 [1]. - The company's main business involves the research, development, production, and sales of thermal management products for new energy vehicle power batteries, fuel vehicle power systems, and energy storage batteries [1]. - The revenue composition of Nanbaichuan includes: 90.15% from battery liquid cooling plates, 7.10% from fuel vehicle thermal management components, 2.30% from other (supplementary) products, 0.34% from other products, and 0.10% from battery enclosures [1]. Group 3: Financial Performance - As of December 23, the number of shareholders for Nanbaichuan reached 29,600, an increase of 211,050% compared to the previous period [2]. - For the period from January to September 2025, Nanbaichuan achieved an operating income of 1.208 billion yuan, representing a year-on-year growth of 32.29% [2]. - The net profit attributable to the parent company was 58.29 million yuan, reflecting a year-on-year increase of 29.30% [2].

Group 1 - The core viewpoint of the news is that Tian Su Measurement has shown fluctuations in its stock performance and financing activities, with a notable drop in stock price on January 5, 2025 [1] - On January 5, 2025, Tian Su Measurement's stock price fell by 2.29%, with a trading volume of 381 million yuan [1] - The financing buy-in amount on January 5 was 29.36 million yuan, while the financing repayment was 19.33 million yuan, resulting in a net financing buy-in of 10.03 million yuan [1] Group 2 - As of January 5, 2025, the total balance of margin trading for Tian Su Measurement was 54.57 million yuan, accounting for 4.75% of its circulating market value [1] - The company has not engaged in any short selling activities on January 5, with no shares sold or repaid [1] - Tian Su Measurement, established on June 17, 2009, specializes in measurement calibration, testing, and certification services across various sectors, including biomedicine, automotive, and renewable energy [1] Group 3 - As of December 23, 2025, the number of shareholders for Tian Su Measurement reached 20,200, reflecting a significant increase of 201,920% [2] - For the period from January to September 2025, the company reported a revenue of 648 million yuan, representing a year-on-year growth of 12.12% [2] - The net profit attributable to the parent company for the same period was 92.99 million yuan, showing an increase of 11.62% year-on-year [2]

Group 1 - The core point of the news is that Jianfa Zhixin experienced a stock price increase of 3.11% on January 5, with a trading volume of 126 million yuan, despite a net financing outflow of 451.27 million yuan for the day [1][2] - On January 5, Jianfa Zhixin had a financing buy amount of 7.2758 million yuan, with a total financing balance of 106 million yuan, representing 6.98% of its market capitalization [2] - The company, established on August 30, 2010, specializes in medical device direct sales and distribution, providing centralized operation services for medical consumables to hospitals [2] Group 2 - Jianfa Zhixin's revenue for the period from January to September 2025 reached 14.861 billion yuan, reflecting a year-on-year growth of 10.18%, while the net profit attributable to shareholders was 230 million yuan, up 45.01% year-on-year [2] - As of December 19, the number of shareholders for Jianfa Zhixin was 28,900, a decrease of 4.56% from the previous period, with an average of 1,747 circulating shares per person, an increase of 4.78% [2]

Group 1 - The core business of Ningbo Xingsui Electronic Technology Co., Ltd. focuses on precision electronic components and mold products, with revenue contributions from automotive electronics (52.32%), smart terminals (26.26%), and other sectors [2] - As of September 30, 2025, the company reported a revenue of 1.328 billion yuan, a year-on-year decrease of 10.13%, and a net profit attributable to shareholders of 119 million yuan, down 38.42% year-on-year [2] - The company has distributed a total of 495 million yuan in dividends since its A-share listing, with 298 million yuan distributed in the last three years [3] Group 2 - On January 5, 2025, Xingsui Technology's stock rose by 0.72%, with a trading volume of 149 million yuan [1] - The financing buy-in amount on January 5 was 24.35 million yuan, with a net financing buy of 7.52 million yuan, and the total financing balance reached 333 million yuan, accounting for 4.70% of the circulating market value [1] - The company’s margin trading and securities lending balance is at a high level, exceeding the 90th percentile over the past year [1]